Shares of EVGN traded down $0.01 during trading hours on Thursday, reaching $1.45. 10,900 shares of the company traded hands, compared to its average volume of 23,324. The firm has a fifty day moving average of $1.52. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.88 and a current ratio of 9.88. Evogene has a 1-year low of $1.39 and a 1-year high of $3.32.
Evogene (NASDAQ:EVGN) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of $0.19 by ($0.35). The company had revenue of $0.19 million for the quarter. Evogene had a negative net margin of 1,103.59% and a negative return on equity of 35.87%.
Evogene Company Profile
Evogene Ltd., a biotechnology company, engages in developing various products for various life science markets through the use of computational predictive biology platform in the United States, Germany, and internationally. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, and human microbiome-based therapeutics.
Featured Story: Cash Flow
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.